Good afternoon, ladies and gentlemen. I am Jason Lettmann, Chief Executive Officer of ALX Oncology Holdings, and as the chairperson of this meeting, it is a pleasure to welcome you to ALX's annual meeting of stockholders. I have asked Harish Shantharam, our Chief Financial Officer, to act as secretary of this meeting and record the minutes. This year, we are again holding a virtual annual meeting of stockholders. We believe in engaging with our stockholders and maximizing their ability to meaningfully engage with us. We are pleased that our stockholders, no matter where they are located in the world today, can participate in the meeting in a virtual format. Before proceeding further, let me introduce the other directors and director nominees of the company who are in attendance: Dr. Corey Goodman, Dr. Daniel Curran, Scott Garland, Rekha Hemrajani, Dr. Alan Sandler, Dr. Chris Takimoto.
I would also like to introduce the members of company management who are also in attendance: Dr. Barbara Klencke, our Chief Medical Officer, Dr. Jeff Knight, our Chief Development and Operating Officer, and Shelley Wong, our SVP Finance and Chief Accounting Officer. Also with us today are Lindsay Brusco, representing KPMG LLP, our independent public accounting firm, Michael Koch, representing Wilson Sonsini Goodrich & Rosati, P.C., our outside corporate counsel, and Trish Hudson, representing Broadridge Financial Solutions, Inc., who is also serving as our Inspector of Election. I will now turn the meeting over to Harish, who will conduct the formal portion of the meeting.
Thank you, Jason. Good afternoon again. Welcome to our 2026 annual meeting. The meeting is being held virtually in accordance with the company's bylaws and Delaware law. The annual meeting is being held for the following purposes: to elect three Class III directors from the nominees named in the accompanying proxy statement to hold office until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal; to approve, on an advisory basis, the compensation of our named executive officers; to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; to transact such other business as may properly come before the annual meeting or any adjournments or postponements thereof.
In order to ensure that the business of the meeting proceeds in an orderly fashion, we ask that you please observe the rules. During the formal meeting, we will address the matters described in the proxy statement, which was first made available to all stockholders on or about April 20, 2026, and is available on our website and the SEC's website. We will then notify you when the voting polls are open. After the voting polls are open, you may vote your shares online anytime during this meeting prior to the closing of the polls. If you have already submitted a proxy to vote your shares, you do not need to submit an online ballot unless you want to change your vote. Your vote will be counted. Once the polls have closed, we will announce the preliminary results of the voting, the formal meeting will be adjourned.
There is a text box on your screen where you can submit your questions regarding voting at any time during the meeting and prior to the end of the formal meeting. After we complete the formal meeting, there will be an opportunity for stockholders to ask questions regarding the company using the text box. We will try to answer as many questions as we have time for, but we may not be able to answer all questions submitted. Notice of the meeting. I have proof by affidavit that notice of this meeting has been duly given and the notice of annual meeting of stockholders, proxy statement, and proxy were mailed on or about April 20, 2026, to stockholders of record on April 15, 2026, the record date for the meeting. Inspector of Election.
We have appointed Trish Hudson, a representative of Broadridge Financial Solutions Incorporated, to act as the Inspector of Election for this annual meeting. The Inspector of Election has signed an oath of office, which will be filed with minutes of this meeting. The Inspector of Election has advised me that we have present virtually or by proxy a sufficient number of shares to constitute a quorum. Therefore, the meeting is duly constituted, and we may proceed with the business. It is now 1:05 P.M. Pacific Time on June 10, 2026, and the polls for each matter to be voted on at this meeting are now open. Proposal one, election of directors. The first item of business is the election of directors. Our board of directors presently has six members.
As indicated in our proxy statement, Daniel Curran, Rekha Hemrajani, and Chris Takimoto are nominated by the board of directors to serve as Class III directors until the annual meeting of stockholders in 2029. Each of these nominees is currently serving as a member of our board of directors. The board of directors recommend that stockholders vote in favor of these nominees, and the proxy solicited by the board will be voted in favor of these nominees. The second item of business is the advisory vote to approve the compensation of our named executive officers as described in the proxy statement, more commonly known as say on pay proposal. Our stockholders are being asked to vote on the following non-binding resolution.
Resolved, that the stockholders of ALX Oncology Holdings Incorporated approve, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement pursuant to Item 402 of the Regulation S-K, including the compensation tables and any related narrative discussion. Our board of directors recommend a vote for the approval on an advisory basis of the compensation of our named executive officers, as disclosed in the proxy statement, and the proxy solicited by the board will be voted in favor of this proposal. Third item of the business is to ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. If the stockholders do not ratify the selection of KPMG LLP as our independent auditor, the board may reconsider the appointment.
The board of directors recommend that the stockholders vote in favor of this proposal, the proxy solicited by the board will be voted in favor of this proposal. It is now 1:07 P.M. Pacific Time on June 10th, 2026, the polls for each matter to be voted on this meeting are now closed. No additional ballots, proxies, or votes, no changes or revocations will be accepted. The proxies and any ballots previously submitted have been tabulated by the Inspector of Election, I have the preliminary voting results. Any votes cast today, including those submitted electronically during the meeting, will be counted in the final tally. Results of voting. Regarding proposal number one, the election of directors, all three nominees were elected to the board.
Regarding proposal number two, the advisory vote on the compensation of our named executive officers, as disclosed in the proxy statement, has been approved. Regarding proposal number three, the appointment of KPMG LLP to serve as our independent auditor for the fiscal year ending December 31, 2026, has been ratified. These are the preliminary results of voting. The final count may vary following final examination of the proxies and ballots. The final results of voting, including any results and proxies recorded during the meeting, will be set forth in the report of the Inspector of Election. The final results will also be reported in our filings with the Securities and Exchange Commission. The annual meeting is now adjourned. Thank you for your attendance. We will now proceed with the Q&A period for our stockholders.
As a reminder, we may make forward-looking statements during this meeting and in the comments and Q&A that follow. Actual results may differ from these statements. I refer you to the documents that we file from time to time with the Securities and Exchange Commission, in particular, our last filed quarterly report on Form 10-Q, as filed with the SEC on May 8th, 2026. These documents contain and identify important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. There are no questions today from our stockholders. Let me turn the call over to Jason.
Great. On behalf of the ALX board and senior management team, I want to thank all of you for attending today's meeting and for the interest you have shown in the progress of ALX Oncology Holdings Inc. We made significant progress over this past year as both our lead program, evorpacept, and our novel EGFR-targeted ADC, ALX2004, have progressed quite well in clinical studies. We are executing on a very focused clinical development plan for evorpacept based on clinical proof of concept established in combination with anticancer antibodies across multiple studies. We are also excited about the progress with ALX2004, as the program has also progressed well in phase I dose escalation. We look forward to sharing additional data on both of these programs, with multiple clinical data readouts expected within the next 12-18 months.
It is clearly a very exciting time at ALX, and we very much appreciate your attendance, and as always, thank you for your support.
The meeting has now concluded. Thank you for your participation. You may now disconnect.